Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCV-086
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HCV-086 is a small molecule antiviral drug candidate developed for the treatment of hepatitis C virus (HCV) infection. It acts as an inhibitor of the NS5B RNA-dependent RNA polymerase enzyme, which is essential for viral replication. The drug was orally administered and underwent early clinical trials to assess its safety and efficacy in patients with chronic hepatitis C. Development was led by Shire ViroPharma in collaboration with Wyeth Pharmaceuticals; however, the program was ultimately discontinued after Phase 1[1][3][4][5].
- Other names
- 691852-36-52-(4-Fluorophenyl)-N-Methyl-6-[(Methylsulfonyl)amino]-5-(Propan-2-Yloxy)-1-Benzofuran-3-Carboxamide3-Benzofurancarboxamide, 2-(4-fluorophenyl)-N-methyl-5-(1-methylethoxy)-6-[(methylsulfonyl)amino]-2-(4-fluorophenyl)-6-(methanesulfonamido)-N-methyl-5-propan-2-yloxy-1-benzofuran-3-carboxamide
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on HCV-086.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCV-086.